Editorial & Columns Voluntary Licensing in Pharmaceutical Industry: Impact on Market Access & Pricing August 1, 2024 | Dr. Anil Kumar Angrish | No Comments | More
Editorial & Columns Divestitures in Pharmaceutical Industry: Indian Experience July 25, 2024 | Dr. Anil Kumar Angrish | No Comments | More
Editorial & Columns Evaluation and Revival of Special Economic Zones in India July 18, 2024 | Dr. Anil Kumar Angrish | No Comments | More
Editorial & Columns Spin-off by Pharmaceutical Companies in India: Improved Focus and Valuation July 11, 2024 | Dr. Anil Kumar Angrish | No Comments | More
Editorial & Columns Competitive Intelligence in Pharmaceutical Industry July 6, 2024 | Dr. Anil Kumar Angrish | No Comments | More
Editorial & Columns Valuation Premium: India-listed Subsidiaries of Pharma and Healthcare MNCs Outshine Parent firms June 26, 2024 | Dr. Anil Kumar Angrish | No Comments | More
Editorial & Columns India and Group of Seven (G7): Connected through Pharmaceuticals June 21, 2024 | Dr. Anil Kumar Angrish | No Comments | More
Editorial & Columns Accessibility and Affordability of Biologics in Low-Middle Income Countries June 12, 2024 | Dr. Anil Kumar Angrish | No Comments | More
Editorial & Columns ESG Frameworks and Pharmaceutical Industry in India June 6, 2024 | Dr. Anil Kumar Angrish | No Comments | More
Editorial & Columns Exchange Rate Fluctuations : Effects on Pharmaceutical Sector in SAARC Nations May 29, 2024 | Dr. Anil Kumar Angrish | No Comments | More